Allianz Asset Management GmbH Sells 5,984 Shares of Cellebrite DI Ltd. $CLBT

Allianz Asset Management GmbH reduced its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 24.4% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,521 shares of the company’s stock after selling 5,984 shares during the quarter. Allianz Asset Management GmbH’s holdings in Cellebrite DI were worth $296,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. OneDigital Investment Advisors LLC increased its stake in Cellebrite DI by 2.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company’s stock worth $556,000 after acquiring an additional 688 shares during the last quarter. Signaturefd LLC increased its position in shares of Cellebrite DI by 68.3% during the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock valued at $32,000 after purchasing an additional 819 shares during the last quarter. Bosun Asset Management LLC increased its position in shares of Cellebrite DI by 2.5% during the 1st quarter. Bosun Asset Management LLC now owns 44,376 shares of the company’s stock valued at $862,000 after purchasing an additional 1,069 shares during the last quarter. Advisors Asset Management Inc. increased its position in shares of Cellebrite DI by 24.7% during the 1st quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company’s stock valued at $119,000 after purchasing an additional 1,214 shares during the last quarter. Finally, Blue Trust Inc. increased its position in shares of Cellebrite DI by 7.2% during the 2nd quarter. Blue Trust Inc. now owns 22,223 shares of the company’s stock valued at $356,000 after purchasing an additional 1,497 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $18.49 on Wednesday. The stock has a market capitalization of $4.43 billion, a PE ratio of -24.33, a P/E/G ratio of 3.36 and a beta of 1.29. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30. The business has a 50-day moving average of $17.72 and a 200 day moving average of $16.91.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $113.28 million during the quarter, compared to analysts’ expectations of $112.33 million. During the same quarter last year, the business posted $0.10 EPS. The business’s revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

CLBT has been the topic of several recent research reports. JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday, October 8th. Lake Street Capital reduced their price objective on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Needham & Company LLC reduced their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Finally, Wall Street Zen upgraded Cellebrite DI from a “hold” rating to a “buy” rating in a research report on Friday, September 26th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus target price of $21.75.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.